Please login to the form below

Not currently logged in

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

Lilly has extended its non-communicable diseases (NCD) partnership programme to South Africa, where it has joined with Project Hope and Donald Woods Foundation (DWF) to help tackle the rise in diabetes.

The Lilly NCD Partnership programme was set up in 2011, with an investment of US$30m over five years. The aim of the partnerships has been to develop new approaches to managing NCDs, such as diabetes, cancer and heart disease, in the developing world.

South Africa is expected to experience the highest growth rate of diabetes in the world over the next 20 years, according to Lilly's corporate communications director, corporate social responsibility, David Marbaugh.

“Ultimately, the goal of the Lilly NCD Partnership is to find new, cost-effective solutions that can be replicated and scaled up by governments around the world,” he said, writing on Lilly's corporate blog. “Our initial focus is on diabetes in disadvantaged communities in Brazil, India, Mexico, and South Africa.”

Part of this process will involve community outreach and support through preventative screening, diagnosis and treatment services, and health education programmes.

According to the World Health Organization (WHO), non-communicable diseases account for 63 per cent of global deaths and nearly 80 per cent of deaths in low- to middle-income countries.

WHO members last week agreed the first-ever global monitoring framework to combat NCDs like heart disease, diabetes, cancer and chronic lung disease with nine voluntary global targets and 25 indicators to help prevent and control them.

12th November 2012

From: Research, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...